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Biopsy and selective recall compared with immediate large
loop excision in management of women with low grade
abnormal cervical cytology referred for colposcopy:
multicentre randomised controlled trial
TOMBOLA Group
ABSTRACT
Objectives To compare the effectiveness of punch biopsy
and selective recall for treatment versus a policy of
immediate treatment by large loop excision in the
management of women with low grade abnormal cervical
cytology referred for colposcopy.
DesignMulticentre individually randomised controlled
trial, nested within the NHS cervical screening
programmes.
Setting Grampian, Tayside, and Nottingham.
Participants 1983 women, aged 20-59, with cytology
showing borderline nuclear abnormalities or mild
dyskaryosis, October 1999-October 2002.
Interventions Immediate large loop excision or up to four
targeted punch biopsies taken immediately with recall for
treatment (by large loop excision) if these showed cervical
intraepithelial neoplasia grade II or III or worse.
Participants were followed for three years, concluding
with an exit colposcopy.
Main outcome measures Clinical end points: cumulative
incidence of cervical intraepithelial neoplasia grade II or
worse and grade III or worse at three years. Clinically
significant anxiety and depression and self reported after
effects assessed six weeks after colposcopy, biopsies, or
large loop excision.
Results 879 women (44%) had a normal transformation
zone at colposcopy and had no further procedures at that
time. Colposcopists were less likely to classify the
transformation zone as abnormalwhen the allocationwas
large loop excision (603 (60%) in the biopsy and selective
recall group; 501 (51%) in the immediate large loop
excision group). Of women randomised to biopsy and
recall, 157 (16%) required a second clinic visit for
treatment. Specimens from almost 60% (n=296) of
women who underwent immediate large loop excision
showed no cervical intraepithelial neoplasia (31%;
n=156) or showed cervical intraepithelial neoplasia grade
I (28%; n=140). The percentages of women diagnosed
with grade II or worse up to and including the exit
examination were 22% (n=216) in the biopsy and recall
arm and 23% (n=228) in the immediate large loop
excision arm. There was no significant difference between
the arms in cumulative incidence of cervical
intraepithelial neoplasia grade II or worse (adjusted
relative for risk large loop excision v biopsy 1.04, 95%
confidence interval 0.86 to 1.25) or grade III or worse
(1.03, 0.79 to 1.34). A greater proportion of disease was
detected at initial investigation and less during follow-up
and at exit in the immediate large loop excision arm, but
time of detection did not differ significantly between
arms. Levels of anxiety and depression and reported pain
did not differ between arms. Higher proportions of women
randomised to large loop excision reported moderate or
more severe bleeding and discharge.
Conclusion A policy of targeted punch biopsies with
subsequent treatment for cervical intraepithelial
neoplasia grade II or III and cytological surveillance for
grade I or less provides the best balance betweenbenefits
and harms for the management of women with low grade
abnormal cytology referred for colposcopy. Immediate
large loop excision results in overtreatment and more
after effects and should not be recommended.
Trial Registration ISRCTN 34841617.
INTRODUCTION
Colposcopy has a central role in the diagnostic inves-
tigation and management of women with premalig-
nant disease of the cervix detected by abnormal
results on cervical cytology in NHS cervical screening
programmes.1 2 In women with low grade abnormal
cytology (see www.cancerscreening.nhs.uk/cervical/)
in recent years there has been a trend towards increas-
ing referral for colposcopy, rather than surveillance by
repeat cytology tests.3 This change in practice evolved
from recognition that some women with low grade
abnormal cytology have underlying high grade cervi-
cal intraepithelial neoplasia4 and might eventually
require colposcopy for persistent cytological
abnormalities.5
At colposcopy, if the cervical transformation zone is
not normal, women can be managed by immediate
removal of the entire transformation zone by large
loop excision. This strategy—known as see-and-treat
—has become increasingly common in NHS cervical
screening programmes.6 It enables full histological
examination, removes any cervical intraepithelial
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neoplasia, and, for most women, is adequate
treatment.7 By avoiding the need for a return visit for
treatment, itminimises non-attendance and potentially
improves the efficiency of clinical services.8-10 Immedi-
ate large loop excision, however, also results in “over-
treatment” (that is, treatment of women without
histologically confirmed cervical intraepithelial neo-
plasia), the extent ofwhichmight be substantial,11 espe-
cially among those with low grade abnormal cytology.
Overtreatment puts women at unnecessary risk of side
effects such as bleeding and infection.11 As the proce-
dure can also have adverse effects on subsequent
reproductive function,12 a more conservative manage-
ment approach might be preferable.
Punch biopsies of the most abnormal areas directed
colposcopically, with recall for treatment (by excision
or ablation) if histology confirms cervical intra-
epithelial neoplasia, offers a more conservative
approach. This strategy, however, also has
drawbacks,13 chiefly with regard to the reliability of
punch biopsies in identifying prevalent high grade cer-
vical intraepithelial neoplasia.14 When only a fraction
of the transformation zone is sampled, the ability of
colposcopists to identify abnormality and target accu-
rately is limited and biased to the most accessible
areas.15 16 Small lesions, microinvasive disease, and
glandular intraepithelial neoplasia might be missed
(“under calling”).17 Moreover, high grade disease
might subsequently develop in women with histologi-
cally confirmed cervical intraepithelial neoplasia
grade I who are not treated.18
No randomised controlled trials have evaluated
immediate large loop excision compared with biopsy
and selective recall inwomenwith low grade abnormal
cytology.Most evidence relates to histological findings
from punch biopsies and large loop excisions in the
same women.17 19-21 Two small cross sectional studies
comparing women managed by biopsy and selective
recall with those managed by immediate large loop
excision found no differences in histological
outcomes,22 23 while one study of women with high
grade abnormal cytology suggested immediate large
loop excision was associated with lower levels of anxi-
ety after the intervention and higher levels of relief.24
There is a complex interplay between adequately
diagnosing and effectively treating the individual
woman at colposcopy, while avoiding unnecessary
interventions and providing an efficient clinical ser-
vice. For the NHS cervical screening programmes
this translates into balancing benefits and harms,
while keeping health service costs at a reasonable
level.25We report results from the trial of management
of borderline and other low grade abnormal smears
(TOMBOLA) on the detection of cervical intra-
epithelial neoplasia, and psychosocial and physical
after effects associated with immediate large loop exci-
sion versus biopsy and selective recall for treatment.
Cost effectiveness is reported in a companion
paper.26
METHODS
The trial involved two randomisations, the first to cyto-
logical surveillance or initial colposcopy and the sec-
ond, within the women assigned to colposcopy, to
biopsy and selective recall or immediate large loop
excision. Results of the first randomisation are
reported in a companion paper.27
Participants and recruitment
Details of eligibility and recruitment, informed con-
sent, and ethical approval are described
elsewhere.27 28 Briefly, all participants had been called
for a routine cytology test as part of the NHS cervical
screening programmes and attended for that test in
October 1999-October 2002. Eligible women were
aged 20-59, had mild dyskaryosis or borderline
nuclear abnormalities, were not pregnant, and had
not had previous destructive or excisional treatment.
Procedures and follow-up
At the colposcopy appointment, consenting women
were immediately randomised to biopsy and selective
recall or immediate large loop excision with a tele-
phone service provided by the health service research
unit of Aberdeen University. Randomisation was stra-
tified by centre, age group, cytology grade, and high
risk human papillomavirus status at recruitment.
Women then underwent colposcopy. Colposcopists
were not blinded to the randomisation. Colposcopic
examination and description of findings followed stan-
dard practice.29 We included women who had an ade-
quate colposcopic examination (the whole of the
transformation zone and any lesions were viewed in
their entirety); those with inadequate colposcopy
were treated according to local NHS protocols. Of
women with adequate colposcopy, those with an
abnormal transformation zone (colposcopic lesion
with acetowhitening with or without capillary vessel
patterns) received the intervention assigned by rando-
misation while those whose transformation zone did
not fulfil the definition of abnormal (henceforth “nor-
mal” transformation zone)were followed-up in general
practice with cytology tests every 12 months.
For biopsy and selective recall, up to four targeted
punch biopsies were taken from the most abnormal
areas. Women with cervical intraepithelial neoplasia
grade II or III (II/III) on histology were recalled for
treatment with large loop excision. Women with no
cervical intraepithelial neoplasia or grade I disease on
histology did not receive any further treatment at that
time and were followed-up in general practice with
cytology tests every six months. In the other arm, the
whole transformation zone, including the abnormality,
was treated immediately by large loop excision. In
both arms women with histology worse than grade
III were treated and subsequently followed-up accord-
ing to standard practice. Follow-up after punch biop-
sies or large loop excisionwaswith cytology tests every
six months in general practice. For all women, cytol-
ogy follow-up results were monitored with subsequent
action (next recommended test date or colposcopy
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referral) based on these. If women were referred for
colposcopy during follow-up, they attended local col-
poscopy clinics and were treated, if required, accord-
ing to local NHS protocols.
About three years after recruitment, women were
invited for an exit colposcopy examination, with
large loop excision if the transformation zone
appeared abnormal; this examination was for the pur-
poses of the trial and was over and above standard
practice in the NHS cervical screening programmes.
Clinicians were blinded to women’s cytology results
and high risk human papillomavirus status at recruit-
ment, their randomisation arm(s), and clinical out-
comes (cytology and histology) since recruitment.
Participants’medical records and hospital and pathol-
ogy databases were reviewed to ascertain any addi-
tional procedures (cytology, colposcopy, histology,
treatment, or admission to hospital) during follow-up.
Colposcopy, cytology, and histology quality assurance
Colposcopistswere accredited by the British Society for
Colposcopy and Cervical Pathology. Cytopathology
andhistopathology laboratories participated in national
quality assurance schemes. For quality assurance pur-
poses, one or two independent pathologists who were
not aware of the original histopathological results cen-
trally reviewed large loop excision and punch biopsy
samples from a random sample of 272 participants. In
252 cases the review diagnosis was identical to the ori-
ginal diagnosis (κ=0.9). Further details of quality assur-
ance exercises are reported elsewhere.2728
Sociodemographic information
At recruitmentwomen completed a sociodemographic
questionnaire.28
Clinical outcomes
The main clinical outcome was established a priori as
the cumulative incidence of cervical intraepithelial
neoplasia grade II ormore severe disease from recruit-
ment up to and including the exit examination as this is
the histological threshold at which women are usually
treated in the NHS cervical screening programmes.
We also considered the subsidiary outcome of cervical
intraepithelial neoplasia grade III or more severe dis-
ease. Eachwomanwas counted only once as a “case”—
at the date of the first occurrence of cervical intra-
epithelial neoplasia grade II or worse—and was classi-
fied according to the highest grade of histology
reported, whether on punch biopsy or large loop exci-
sion. Women with a normal transformation zone at
initial colposcopy were assumed to have no cervical
intraepithelial neoplasia at that time.
Psychosocial and physical morbidity
Psychosocial sequelae were assessed throughout fol-
low-up and will be reported in detail elsewhere. A sub-
group of women was invited to complete the hospital
anxiety and depression scale30 six weeks after colpo-
scopy and related interventions. This subgroup
comprised all women recruited from February 2001
onwards in the colposcopy arm of the trial who con-
sented to randomisation at the colposcopy appoint-
ment (n=989). These women were also asked, by
means of a postal questionnaire administered together
with the six week psychosocial assessment, to provide
information on any physical after effects (pain, bleed-
ing, and discharge) they had experienced. In addition,
clinic staff recorded complications occurring during
colposcopy, biopsies, and large loop excision.
Statistical analysis
All analyses were by intention to treat. To accommo-
date variability between participants in length of fol-
low-up, each woman accrued person years from the
randomisation date until the date of the exit appoint-
ment for those who attended and, for others, the date
the exit appointment was scheduled or the date they
requested to leave the trial, had a hysterectomy, died,
or moved from the area.We compared the cumulative
incidence of cervical intraepithelial neoplasia grade II
or worse for immediate large loop excision versus
biopsy and selective recall using relative risks, com-
puted by Poisson regression. Risk estimates were
adjusted only for the randomisation stratification vari-
ables; adjustment for a range of other sociodemo-
graphic and lifestyle factors had little effect. To
investigate heterogeneity in detection of cervical intra-
epithelial neoplasia by the management policies, we
repeated analyses stratifying by age at recruitment
(20-29, 30-59), recruitment cytology (mild dyskaryo-
sis, borderline nuclear abnormalities), and whether
women had had previous cytology showing borderline
nuclear abnormalities.Kaplan-Meier curves examined
the risk of cervical intraepithelial neoplasia grade II or
worse over time, with arms compared by the log rank
test. All analyses were repeated for cervical intra-
epithelial neoplasia grade III or worse. We computed
two estimates of overtreatment by a policy of immedi-
ate large loop excision11 based on outcomes after initial
colposcopy and large loop excision (that is, without
follow-up). Firstly, we used the National Cancer Insti-
tute definition: percentage of specimens found to have
no cervical intraepithelial neoplasia/grade I disease,31
and, secondly, we used the NHS cervical screening
programme definition: percentage of specimens
found to have no cervical intraepithelial neoplasia.2
We used z tests to compare the proportions of
women who scored ≥11 on the anxiety subscale and
≥8 on the depression subscale of the hospital anxiety
and depression scale and who reported pain, bleeding,
and discharge (any, and that rated asmoderate ormore
severe) at six weeks after the last procedure (whether
colposcopy, punch biopsies, or large loop excision).
Wilcoxon tests compared reported durations of pain,
bleeding, and discharge.
Statistical power
We estimated that about 2130 women would give 86%
power to detect a relative risk of 1.25 in the cumulative
incidence of cervical intraepithelial neoplasia grade II
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or worse, assuming overall cumulative incidence of
15% (α=0.05, two sided test).
RESULTS
Figure 1 summarises numbers of women recruited,
randomised, and followed-up. Of the 2065 women
who attended for colposcopy, 2039 consented and
were randomised. One woman did not have a colpo-
scopy and55 (2.7%)had an inadequate colposcopyand
were excluded; 1000 were randomised to biopsy and
selective recall and 983 to immediate large loop exci-
sion. At the exit examination 689 (70.0%) women in
Randomised to initial colposcopy (n=2216)
Attended exit examination (n=689, 70.0%)
  CIN II/III outcome information from exit examination and medical
    record abstraction
Did not attend exit examination (n=297, 30.0%)
  CIN II/III outcome information from medical record abstraction only
Attended for colposcopy  (n=2065) Did not have colposcopy (n=151)
Consented to randomisation (n=2040) Did not consent to randomisation (n=25)
Randomised (n=2039) Not randomised (n=1)
Immediate LLETZ (n=983) Biopsy and selective recall (n=1000)
Had adequate colposcopy and
included in comparison (n=1983)
Inadequate colposcopy (n=55) Colposcopy not done (n=1)
Attended exit examination (n=637, 63.7%)
  CIN II/III outcome information from exit examination and medical
    record abstraction
Did not attend exit examination (n=363, 36.3%)
  CIN II/III outcome information from medical record abstraction only
Abnormal TZ (n=504)Normal TZ (n=479)
Had LLETZ (n=474) Deviation from protocol:
biopsies taken (n=1)
Had biopsies (n=592)
No CIN or
CIN I (n=432)
Had inadequate
biopsies and
not repeated (n=3)
Deviations from protocol (n=11)
 Returned and had cold coagulation (n=3)
 Returned and not treated (no acetowhite
    on colposcopy) (n=1)
 Returned after pregnancy for biopsies (n=2)
 Moved away before treatment appointment
    (n=1)
 Impending hysterectomy (n=3)
 Not recalled for treatment, followed
    colposcopically (n=1)
CIN II/III+
(n=157)
Returned for LLETZ (n=146)
Deviations from protocol (n=30): 
  Biopsy only (n=20)
 Biopsy and cold coagulation
    (n=3)
 No biopsy or treatment
    undertaken (n=3)
 Repeat colposcopy
    appointment and had
    normal TZ (n=3)
 Condyloma removed (n=1)
Abnormal TZ (n=604)
Deviations from protocol (n=11): 
  Had immediate LLETZ (n=6) 
 Had biopsies and cold
    coagulation (n=2) 
 Had cold coagulation only (n=1) 
 Had repeat colposcopy
    appointment and had
    normal TZ (n=1)
 Had LLETZ under general
    anaesthetic (n=2)
Normal TZ (n=396)
Fig 1 | Numbers of women randomised and followed up and deviations from protocol (LLETZ=large loop excision of
transformation zone; TZ=transformation zone, CIN=cervical intraepithelial neoplasia)
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the immediate large loop excision armand637 (63.7%)
in the other arm attended.
Characteristics of participants
The trial arms were balanced in terms of the stratifica-
tion variables at randomisation and other sociodemo-
graphic and lifestyle factors (table 1). In each arm
around 43% were aged 20-29 and 57% aged 30-59.
Slightly over a third had mild dyskaryosis at recruit-
ment; of these, 8% had had previous cytology showing
borderline nuclear abnormalities. Almost a quarter of
those with borderline nuclear abnormalities at recruit-
ment had had a previous smear with the same result.
Most women were white and in full or part time
employment, and almost 20% had obtained a college
or university degree.
Colposcopic impression and related histology: cross
sectional results
Overall, 44% of women had a normal transformation
zone at colposcopy and had no further procedures at
that time. This percentage was higher in women who
were older (53% in those aged 30-59 v 34% in those
aged 20-29) or were recruited with cytology showing
borderline nuclear abnormalities (52% v 30% of those
with mild dyskaryosis).
In comparing the trial arms, the proportion judged
to have an abnormal transformation zone was signifi-
cantly lower in the immediate large loop excision arm
(51%) than the biopsy and recall arm (60%, z=5.04,
P<0.001; table 2). Fewer women in the immediate
large loop excision arm had no cervical intraepithelial
neoplasia (16% v 27%) and grade I disease on histology
(14% v 17%) and the frequency of cervical intra-
epithelial neoplasia grade II or worse was slightly
higher in this arm (21% v 16%). Three women had dis-
easeworse than cervical intraepithelial neoplasia grade
III (one cervical glandular intraepithelial neoplasia
and two squamous carcinomas (FIGO stage IA1,
FIGO stage IB)), two of whom were in the large loop
excision arm.
Diagnostic yield of immediate large loop excision
In the immediate large loop excision arm, 474 of the
501 women with an abnormal transformation zone
underwent large loop excision (fig 1). An average of
2.3 large loop excision procedures were undertaken
per case of cervical intraepithelial neoplasia grade II
or worse detected; 4.7 large loop excision procedures
were done per case of grade III or worse.
Recall for treatment and default after punch biopsies
In 157 women punch biopsies indicated cervical intra-
epithelial neoplasia grade II or worse (fig 1), thus 16%
of women randomised to biopsy and recall (and 26%
with an abnormal transformation zone in that arm)
potentially needed to return to the clinic for treatment.
Three women were due to have a hysterectomy and
were not offered treatment, another was followed col-
poscopically, and another moved out of the area. The
Table 1 | Characteristics of women at recruitment, by trial arm. Figures are numbers
(percentages) of women
Biopsy
and recall
Immediate large
loop excision
Total women randomised 1000 (100) 983 (100)
Cytological status at recruitment:
Mild dyskaryosis, with previous borderline nuclear abnormalities 32 (3) 26 (3)
Mild dyskaryosis, no previous borderline nuclear abnormalities 328 (33) 318 (32)
Borderline nuclear abnormalities, with previous borderline nuclear
abnormalities
147 (15) 141 (14)
Borderline nuclear abnormalities, no previous borderline nuclear
abnormalities
493 (49) 498 (51)
Age (years):
20-29 433 (43) 426 (43)
30-39 273 (27) 273 (28)
40-49 213 (21) 203 (21)
50-59 81 (8) 81 (8)
Human papillomavirus status*:
High risk 397 (40) 385 (39)
Not high risk 522 (52) 514 (52)
Not known† 81 (8) 84 (9)
Trial centre:
A 336 (34) 326 (33)
B 231 (23) 229 (23)
C 433 (43) 428 (44)
Deprivation category‡:
1 (least deprived) 130 (13) 125 (13)
2 191 (19) 175 (18)
3 164 (16) 178 (18)
4 261 (26) 273 (28)
5 (most deprived) 254 (25) 232 (24)
Ethnic group:
White 953 (95) 936 (95)
Other§ 42 (4) 38 (4)
Not stated 5 (1) 9 (1)
Education/training after school:
None 261 (26) 257 (26)
Through work with formal qualifications 184 (18) 182 (19)
Qualification other than degree from college/university 267 (27) 259 (26)
University/college degree 173 (17) 203 (21)
Current student 111 (11) 77 (8)
Not stated 4 (0) 5 (1)
Employment status:
Full time paid employment 482 (48) 507 (52)
Part time paid employment 244 (24) 217 (22)
Student 111 (11) 77 (8)
Not in paid employment 160 (16) 179 (18)
Not stated 3 (0) 3 (0)
Marital status:
Married/living as married 547 (55) 520 (53)
Divorced/separated/widowed 136 (14) 136 (14)
Single 309 (31) 316 (32)
Not stated 8 (1) 11 (1)
Ever been pregnant:
Yes 685 (69) 649 (66)
No 309 (31) 329 (33)
Not stated 6 (1) 5 (1)
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remainder (n=152) returned for treatment, including
two women who had become pregnant and returned
to undergo further biopsies after their pregnancies
were completed.
Overtreatment by large loop excision
In the immediate large loop excision arm, 59% (432) of
the women from whom specimens were taken had no
cervical intraepithelial neoplasia (31%) or grade I dis-
ease (28%). Thus according to the National Cancer
Institute’s definition, 59% of womenwere overtreated;
by the NHS cervical screening programme definition,
31% were overtreated.
Cumulative incidence of cervical intraepithelial neoplasia
over three years
The cumulative incidence of cervical intraepithelial
neoplasia grade II or worse was slightly higher in the
immediate large loop excision arm (84/1000 person
years v 79/1000), but the adjusted relative risk was
not significantly raised (relative risk large loop excision
v biopsy 1.04, 0.86 to 1.25) (table 3). The rates of cer-
vical intraepithelial neoplasia grade III or worse in
each arm were about half those of cervical intra-
epithelial neoplasia grade II or worse and the adjusted
relative risk did not differ from unity (1.03, 0.79 to
1.34).
There was no difference between the policies in the
detection of cervical intraepithelial neoplasia grade II
or worse or grade III or worse over three years in sub-
groupsdefinedbyageorrecruitmentcytology(table 4).
Similarly, when we restricted the analysis to the 1637
women with no previous cytology showing borderline
nuclear abnormalities, the occurrence of cervical intra-
epithelial neoplasia grade II or worse did not differ
between the arms (adjusted relative risk 0.99, 0.81 to
1.22; P=0.956).
Timing of detection of cervical intraepithelial neoplasia
grade II or worse
Almost 90% of cases of cervical intraepithelial neopla-
sia grade II or worse in the immediate large loop exci-
sion arm were diagnosed as a result of the initial
colposcopy and any related procedures, compared
with 74% in the biopsy and recall arm (table 3). In
the biopsy and recall arm a quarter of cases were
detected during follow-up (15%, n=32) and at exit
(11%, n=24), compared with 12% in the immediate
large loop excision arm (8%, n=18, during follow-up;
4%, n=8, at exit). Time of detection, however, was not
significantly different between the arms (fig 2; log rank
χ2 0.856, df=1, P=0.355). These patterns were the same
when we repeated the analysis for cervical intra-
epithelial neoplasia grade III or worse (Kaplan-Meier
curve not shown; log rank χ2 0.358, df=1, P=0.550).
Morbidity
In the immediate large loop excision arm there were
two cases of haemorrhage and seven vasovagal events
in the clinic. In the other arm, there was one case of
haemorrhage and one vasovagal event after punch
biopsy and onewoman haemorrhaged after treatment.
Women’s reports of pain after the initial colposcopy
and related procedures did not differ by arm (table 5).
Although the occurrence of any bleedingwas higher in
the biopsy and recall arm, this was of significantly
longer duration (P<0.001) and more likely to be mod-
erate or more severe (P=0.022) in the immediate large
loop excision arm. Similar findings were seen for dis-
charge.
A slightly higher percentage of women in the biopsy
and recall arm scored ≥11 on the hospital anxiety and
depression scale anxiety subscale six weeks after the
procedure, but this was not significant (P=0.203).
There was no significant difference in the frequency
of depression (subscale score ≥8) by arm (P=0.239).
DISCUSSION
In this randomised controlled trial comparingmanage-
ment options at colposcopy for women with low grade
abnormal cytology, colposcopists were significantly
less likely to classify the transformation zone as abnor-
mal in women who were to be managed by large loop
excision than in those who were to be managed by
punch biopsies. Althoughmore cervical intraepithelial
neoplasia grade II or worse was detected initially in the
immediate large loop excision arm, and the incidence
of disease during follow-up and at the exit examination
was higher in the biopsy and recall arm, the timing of
detection of disease did not differ significantly between
Biopsy
and recall
Immediate large
loop excision
Parity:
0 419 (42) 436 (44)
1 162 (16) 144 (15)
≥2 397 (40) 386 (39)
Not stated 22 (2) 17 (2)
Current contraception:
Use of pill or other hormonal contraceptives only 395 (40) 328 (33)
Use of barrier contraceptive only 133 (13) 144 (15)
Use of hormonal and barrier contraceptives 33 (3) 34 (3)
None 436 (44) 474 (48)
Missing 3 (0) 3 (0)
Physical activity:
<1 time/week 400 (40) 396 (40)
1-3 times/week 225 (23) 228 (23)
>3 times/week 360 (36) 346 (35)
Not stated 15 (2) 13 (1)
Smoking status:
Never smoked 453 (45) 467 (48)
Former smoker 171 (17) 160 (16)
Current smoker 367 (37) 348 (35)
Not stated 9 (1) 8 (1)
*Based on polymerase chain reaction analysis with GP5+/6+ consensus primers, followed by enzyme
immunoassay for detection of 14 “high risk” human papillomavirus types (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68).
†Includes women whose samples were inadequate for analysis (n=14) and women who did not have human
papillomavirus test at recruitment (n=151).
‡Carstairs deprivation measure based on population fifths assigned from address of residence at recruitment.
§Black-Caribbean n=29; Black-African n=4; Black-other n=8; Indian n=8; Pakistani n=10; Bangladeshi n=2;
Chinese n=7; other ethnic group n=12.
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the arms. Thus, overall there was no significant differ-
ence in ability of the policies to detect grade II neopla-
sia or worse over three years. This finding did not vary
by age group or recruitment cytology. Specimens from
28% of women who underwent immediate large loop
excision showed grade I neoplasia, and a further 31%
had no cervical intraepithelial neoplasia. Of women
managed by punch biopsies, 16% were recalled for
treatment. Higher proportions of women randomised
to large loop excision reported moderate or more
severe bleeding and discharge. As no aspect of screen-
ing is without some disadvantages, the challenge in
synthesising these findings is that of maximising bene-
fits while minimising harms.
Colposcopic thresholds
The higher percentage of women assessed as having an
abnormal transformation zone in the biopsy and recall
arm could be a true difference or a result of variation in
colposcopic assessment between observers,32 33 but
these explanations are unlikely given that the study
was randomised and the randomisation was stratified
by centre (each colposcopist worked in one centre). In
addition, comparison of the seven trial colposcopists
and one external colposcopist found moderate to
high agreement between raters on presence of aceto-
whitening in colposcopic images from 124 women.
More plausible explanations are that colposcopists
might be more reluctant to do a large loop excision if
there is ambiguity about the normality of the transfor-
mation zone, or if colposcopists’ threshold to identify a
relevant lesion and perform a biopsy is lower if the
proposed intervention is punch biopsy. As the higher
frequency of intervention in the biopsy and recall arm
did not result in significantly higher detection of high
grade cervical intraepithelial neoplasia, this suggests
that the colposcopic threshold at which the decision is
made to undertake punch biopsy is too low.
Targeted biopsies and missed prevalent disease
The concerns about the safety of a policy of biopsy and
selective recall, in terms of missing relevant disease,
tend to have been expressed in the context of women
with high grade abnormal cytology,17 in whom the
underlying prevalence of high grade disease would
be higher than in women with low grade abnormal
cytology. In some instances where prevalent disease
has been missed this was probably due, at least in
part, to inadequate biopsy practice. A trial of women
with low grade abnormal cytology in theUnited States,
known as ALTS, found that diagnostic accuracy
dependedmore on the number of biopsies taken rather
than the colposcopist’s experience.34 Within the cur-
rent trial, colposcopic practice followed NHS cervical
screening programme guidelines,2 which recommend
a minimum of two punch biopsies; this was done in
more than 90% of women. Despite this, the frequency
of cervical intraepithelial neoplasia grade II or worse
(and of grade III or worse) was still higher after the
initial colposcopy in the large loop excision arm, sug-
gesting that pathologists findmorehigh gradedisease if
they have large loop excision samples than if they have
punch biopsy samples.
If prevalent high grade diseasewasmissed inwomen
onbiopsy and recall, wewould expectmore high grade
lesions to be detected during follow-up and at exit
examination in this arm, which is what we saw. The
difference between arms, however, was not pro-
nounced (3% and 2% of women on biopsy and recall
had cervical intraepithelial neoplasia grade II or worse
Table 2 | Colposcopic impression and histological* outcome of initial colposcopy examination and related procedures, by
trial arm (cross sectional analysis)
Biopsy and recall Immediate large loop excision
No (% of those
in arm)
% of those with abnormal
transformation zone
No (% of those
in arm)
% of those with abnormal
transformation zone
Total women randomised 1000 (100) — 983 (100) —
Normal transformation zone†‡ 397 (40) — 482 (49) —
Abnormal transformation zone§
Total 603 (60) 100 501 (51) 100
No CIN 269 (27) 45 156 (16) 31
CIN grade I 168 (17) 28 140 (14) 28
CIN grade II or worse¶ 160 (16) 27 202 (21) 40
CIN grade II 77 — 100 —
CIN grade III or worse¶ 83 — 102 —
Other** 6 (0.6) 1 3 (0.3) 0.6
CIN=cervical intraepithelial neoplasia.
*Represents most severe histology recorded after initial colposcopy (that is, for women in whom biopsy and large loop excision results did not
correspond, most severe has been recorded).
†No abnormal transformation zone on colposcopy; women did not have any further procedures at this time.
‡Biopsy and recall figure includes 396 women with normal transformation zone on initial colposcopy, plus one woman originally found to have
abnormal transformation zone who returned for treatment and at repeat colposcopy had normal transformation zone; immediate large loop excision
figure includes 479 women with normal transformation zone at initial colposcopy, plus three women with abnormal transformation zone who were
not treated immediately and, at repeat colposcopy, were found to have normal transformation zone.
§Abnormal transformation zone at colposcopy and women went on to receive intervention assigned by randomisation.
¶Three women had disease worse than CIN III, one in biopsy and recall arm and two in immediate large loop excision arm.
**Includes three women with inadequate histology (biopsy and recall arm), and six with no histology (three in each arm).
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detected during follow-up and at exit, respectively,
compared with 2% and 1% on immediate large loop
excision) and was mainly accounted for by grade II
disease (32/56 were grade II in the biopsy and recall
group; 15/26were grade II in the immediate large loop
excision group). In addition, there was no significant
difference between arms in the timing of detection of
disease. Moreover, in each arm 15 of the cases that
occurred during follow-up were in women with a nor-
mal transformation zone at initial colposcopy, a few of
whom probably harboured lesions at recruitment that
were undetected at that time. As the frequency of
microinvasive and invasive disease over three years
was low (two cases in each arm), and there was no dif-
ference in the cumulative disease incidence between
arms, these observations suggest that biopsy and recall
is not associated with delays that increase the risk of
high grade or invasive disease, at least over three
years. Thus although some undercalling might occur
at the time of colposcopy, the policy is safe for theman-
agement of women with low grade abnormal cytology
within the NHS cervical screening programmes.
Overtreatment by large loop excision and risk of high grade
disease in women with untreated grade I neoplasia
Despite the higher threshold for intervention in the
immediate large loop excision arm, 31% of specimens
contained no cervical intraepithelial neoplasia. This is
well above the NHS cervical screening programme
standard (<10%) and is partly due to the trial protocol
where all abnormalities were treated by large loop
excision; in the real world, alternatives are available.
In almost 30% of women who had immediate large
loop excision, the histology indicated cervical
intraepithelial neoplasia grade I; the proportion with
grade I disease was the same among women rando-
mised to biopsy and recall who had an abnormal trans-
formation zone. Much of the debate around the
relative benefits andharms of themanagement policies
hinges onwhether grade I disease needs to be removed
to reduce risk of subsequent high grade disease. If so,
women with cervical intraepithelial neoplasia grade I
managed by a policy of immediate large loop excision
would not be considered to have had unnecessary
treatment, while those managed by punch biopsies
and selective recall might be considered to be under-
treated. In ALTS, 13% of women with grade I neopla-
sia developed grade II/III disease over two years.35 As
screening programmes reduce but do not eliminate
risk of disease,25 the key issue for a policy of biopsy
and recall is whether incident high grade cervical intra-
epithelial neoplasia in women with grade I disease
would be detected and treated as part of routine fol-
low-up before it progresses to invasive disease. In the
current trial, follow-up was based on standard NHS
cervical screening programme protocols. Among the
168 women with cervical intraepithelial neoplasia
grade I in the biopsy and recall arm, 12 (7.1%) cases
of grade II disease or worse were diagnosed during
follow-up and a further five (3.0%) were found at the
exit examination (although this was not part of stan-
dard follow-up); no cases were more severe than
grade III. This suggests that the risk of incident high
grade disease in women with low grade abnormal
cytology in the NHS cervical screening programmes
and grade I neoplasia on punch biopsy is relatively
low and that most cases will be safely detected (and
treated) during routine follow-up.
Table 3 | Incidence of cervical intraepithelial neoplasia grade II or grade III or worse after three years of follow-up, by trial
arm and period of follow-up
Biopsy and recall Immediate large loop excision
Relative risk*
(95% CI), P value
No (% of those
in arm)
% of disease
detected
No (% of those
in arm)
% of disease
detected
Total women randomised 1000 (100) — 983 (100) — —
Total person years of follow-up 2731 — 2725 — —
Cervical intraepithelial neoplasia grade II or worse
Total cases† 216 (22) 100 228 (23) 100 —
At initial colposcopy 160 (16) 74 202 (21) 89 —
At follow-up 32 (3) 15 18 (2) 8 —
At exit examination 24 (2) 11 8 (1) 4 —
Cumulative incidence per 1000
person years§
79 — 84 — 1.04 (0.86 to 1.25),
P=0.687
Cervical intraepithelial neoplasia grade III or worse
Total cases† 107 (11) 100 113 (11) 100 —
At initial colposcopy 83 (8) 78 102 (10) 90 —
At follow-up 19 (2) 18 10 (1) 9 —
At exit examination 5 (1) 5 1 (0.1) 1 —
Cumulative incidence per 1000
person years§
39 — 41 — 1.03 (0.79 to 1.34),
P=0.841
*Relative risk (with biopsy and recall as reference) based on total number of cases and adjusted for age (20-29, 30-39, 40-49, 50-59), cytology at
recruitment (mild dyskaryosis, borderline nuclear abnormalities), centre (Grampian, Tayside, Nottingham), and high risk human papillomavirus status
(positive, negative, unknown).
‡Includes four women who had disease worse than cervical intraepithelial neoplasia grade III; three detected after initial colposcopy and treatment
(one in biopsy and recall arm, two in immediate large loop excision arm), and one detected during follow-up in biopsy and recall arm.
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Morbidity associated with management policies
The higher occurrence of haemorrhage and vasovagal
events in the large loop excision arm was unsurprising
given that both are recognised risks of the procedure.11
Although clinically important, recording complications
during procedures does not capture other physical after
effects that women might experience, such as ongoing
pain or discharge. Our analysis in this paper was by
intention to treat so probably underestimates the true
difference between policies. An analysis of after effects
based on management received by women is reported
elsewhere.36 As size of excision has previously been
positively associated with occurrence of bleeding,37 the
observed higher frequencies of moderate or more
severe bleeding and discharge in the immediate large
loop excision armmight have been expected.
As women who participate in trials might be system-
atically different from those who do not, it is not clear
that our findings regarding overall levels of anxiety or
depression will be generalisible to all women with low
grade abnormal cytology. The internal comparison of
the trial arms, however, is valid. Our observation of no
notable difference between arms in anxiety after the
procedure contrasts with the results of Balasubramani
et al.24 In a non-randomised study of 272 women with
high grade smear results, women who had immediate
large loop excision reported lower anxiety and greater
relief oneweek after the intervention than those under-
going biopsy and recall for treatment. The instruments
for assessing outcomes, and timing of these, differed
from those in our trial. In addition, information given
to women with high grade abnormal cytology, and
their expectations and emotional and psychosocial
responses, might differ from women with low grade
abnormal cytology.
Recall for treatment: costs and default
One of the major potential limitations of a policy of
biopsies and selective recall is theneed for a proportion
of women (16% of those randomised) to return for
treatment. The colposcopy clinic incurs the cost of an
additional appointment and women themselves
experience both inconvenience and time and travel
costs, the latter estimated at more than £27 (€32, $44)
per clinic visit.38 In our economic analysis, the cost
effectiveness ratios of the two management policies
did not differ significantly.26 What remains unknown,
however, is how women themselves balance the
advantage with see-and-treat of avoiding the cost and
inconvenience of a second clinic visit against the risk of
overtreatment and increased physical after effects.
A further potential drawback of biopsy and recall is
that women might not attend the treatment appoint-
ment, therefore increasing their risk of developing
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Fig 2 | Cumulative proportion of women developing cervical
intraepithelial neoplasia grade II or more severe disease from
trial recruitment up to and including exit examination, by trial
arm (χ2 from log rank test)
Table 4 | Incidence of cervical intraepithelial neoplasia grade II or grade III or worse after three years of follow-up, stratified
by age and recruitment cytology
Outcome and subgroup
Biopsy and recall Immediate large loop excision
Relative risk*
(95% CI) P value
No (%)
of cases
Cumulative
incidence
No (%) of
cases
Cumulative
incidence
Cervical intraepithelial neoplasia grade II or worse
Age (years):
20-29 134 (31) 116 137 (32) 117 1.01 (0.80 to 1.29) 0.904
30-59 82 (14) 52 91 (16) 59 1.07 (0.79 to 1.44) 0.657
Cytology†:
Mild dyskaryosis 129 (36) 134 120 (35) 125 0.90 (0.70 to 1.16) 0.424
Borderline nuclear abnormalities 87 (14) 49 108 (17) 61 1.24 (0.94 to 1.65) 0.132
Cervical intraepithelial neoplasia grade III or worse
Age (years):
20-29 69 (16) 60 69 (16) 59 0.99 (0.71 to 1.38) 0.950
30-59 38 (7) 24 44 (8) 28 1.10 (0.71 to 1.70) 0.673
Cytology‡:
Mild dyskaryosis 67 (19) 69 59 (17) 62 0.84 (0.59 to 1.19) 0.332
Borderline nuclear abnormalities 40 (6) 23 54 (8) 31 1.35 (0.90 to 2.04) 0.146
*Comparison for immediate large loop excision v biopsy and recall (reference group). Adjusted for age (20-29, 30-39, 40-49, 50-59, as appropriate),
recruitment cytology (mild dyskaryosis, borderline nuclear abnormalities, as appropriate), centre (Grampian, Tayside, Nottingham), and high risk
human papillomavirus status (positive, negative, unknown).
†Result of cytology test that triggered recruitment into trial; women might have had up to one additional smear showing borderline nuclear
abnormalities in previous three years.
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invasive disease. The high rate of return for treatment
in the biopsy and recall arm probably reflects the com-
mitment of trial participants and might not generalise
to routine clinical practice.
Strengths and limitations
This trial was large, population based, and pragmatic.
The overall participation ratewas 52%.As regards gen-
eralisibility of the results to theNHS cervical screening
programme, the ratio of borderline nuclear abnormal-
ities to mild recruitment smear results among partici-
pants (1.8:1) was close to that reported for the
programme screening age group in 2004-5 (1.9:1).39 40
Despite strenuous attempts to maximise
attendance,28 a third of participants did not attend the
exit examination. Thosewho did not attendweremore
likely to be young, be from non-white ethnic groups,
have only mildly abnormal results at recruitment, live
in areas in the two most deprived categories, and be
smokers at recruitment. As several of these are risk fac-
tors for cervical intraepithelial neoplasia grade II/III
and cervical cancer,41-43 the overall cumulative inci-
dence of cervical intraepithelial neoplasia grade II or
worse was probably underestimated. The extent of the
underestimation is probably small, however, as only
32 new cases were found at the exit examination
(2.4% of attendees). In addition, the incidence of cervi-
cal intraepithelial neoplasia grade II orworse up to, but
not including, the exit examination (14% and 33% for
those with recruitment smears showing borderline
nuclear abnormalities and mild dyskaryosis, respec-
tively), were similar to figures from two studies that
followed participants in the NHS cervical screening
programme with borderline nuclear abnormalities
and mild dyskaryosis for five years (13% and 28%,44
13% and 36%45). When we restricted our analysis to
women who had attended the exit examination, the
results were unchanged (adjusted relative risk for
grade II or worse, large loop excision v biopsy 1.02,
0.81 to 1.28).
A greater proportion of women in the biopsy and
selective recall arm had their clinical outcomes deter-
mined from review of medical and hospital records
and pathology databases. As some women who did
not attend the exit examination might have had
undiagnosed disease, the differential attendance at
exit by arm is a limitation of the trial. In theory the
burden of cervical intraepithelial neoplasia might
have been underestimated to a greater extent in the
biopsy and recall arm than in the other arm, meaning
that we failed to detect a true difference between the
arms. Given the low frequency of high grade cervical
intraepithelial neoplasia at exit, however, only a few
additional cases would have been detected had atten-
dance in the biopsy and recall arm been as high as in
the other arm, and this would not have had a sufficient
impact on cumulative incidence to change the main
findings.
In recognition of its limitations, the role of colpo-
scopy was restricted to categorising the transformation
zone as normal or abnormal. Although large loop exci-
sion became the most common treatment method for
cervical intraepithelial neoplasia during the 1990s,
ablative treatment is still widely used and might offer
Table 5 | Morbidity at six weeks after procedure* and incidence of clinically significant anxiety and depression by trial arm†.
Figures are numbers (percentages) unless stated otherwise
Biopsy and recall
(n=361‡)
Immediate large loop excision
(n=400§)
Difference in % between arms
(95% CI) P value
Pain:
Any pain 143 (39.7) 153 (38.7) −1.0 (−8.0 to 6.0) 0.781
Median (IQR) duration (days) 2 (1-3) 2 (1-3) 0.782
Moderate or more severe 68 (19.0) 75 (19.2) 0.2 (−5.4 to 5.9) 0.935
Bleeding:
Any bleeding 182 (50.4) 171 (43.5) −6.9 (−14.0 to 0.2) 0.058
Median (IQR) duration (days) 3 (2-5) 8 (3-20) <0.001
Moderate or more severe 55 (15.3) 84 (21.9) 6.5 (1.0 to 12.1) 0.022
Discharge:
Any discharge 122 (33.9) 139 (35.3) 1.3 (−5.5 to 8.1) 0.709
Median (IQR) duration (days) 3 (2-7) 9 (3-14) <0.001
Moderate or more severe 46 (12.8) 84 (21.4) 8.6 (3.2 to 13.9) 0.002
Anxiety¶ 32 (9.4) 26 (6.8) −2.6 (−6.6 to 1.4) 0.203
Depression** 27 (7.9) 22 (5.7) −2.2 (−5.9 to 1.5) 0.239
IQR=interquartile range.
*Questionnaires administered about six weeks after last procedure, whether colposcopy, punch biopsies, or large loop excision, to 502 women in
biopsy and recall arm and 487 in immediate large loop excision arm.
†Intention to treat analyses. Biopsy and recall group includes women managed by colposcopy only, colposcopy and punch biopsies, or colposcopy,
punch biopsies, and large loop excision; immediate large loop excision group includes women managed by colposcopy only, or colposcopy and large
loop excision.
‡Number who responded to questionnaire; number who responded to individual questions on pain, bleeding, and discharge varied between 358 and
361; anxiety based on 341 respondents; depression based on 343 respondents.
§Number who responded to questionnaire; numbers who responded to individual questions on pain, bleeding, and discharge varied between 385
and 395; anxiety based on 382 respondents; depression based on 387 respondents.
¶≥11 on hospital anxiety and depression scale anxiety subscale.
**≥8 on hospital anxiety and depression scale depression subscale.
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advantages over excision, especially for young nulli-
parous women.46 47 In the current trial, women treated
after punch biopsies had large loop excision (to ensure
complete histological assessment of the transformation
zone), but we consider that our findings would also
apply to a policy of subsequent ablative treatment.
Conclusions
When carried out in the context of a quality assured
screening programme with recognised colposcopy
accreditation and national standards for colposcopy,
targeted punch biopsy and selective treatment of high
grade cervical intraepithelial neoplasia provides the
best balance between benefits and harms for the man-
agement of women seen for colposcopic assessment of
low grade abnormal cytology. The policy does not
miss important disease, and, although a proportion of
women are recalled for treatment, it is as cost effective
as immediate large loop excision. Immediate large
loop excision is not recommended as there is a consid-
erable risk of overtreatment and more after effects.
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